Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics

Definitions

• This invention relates to solid forms of 3-(4-(aminomethyl)-l-(5-methyl-7H-pyrrolo [2,3- d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and salts thereof, compositions comprising them, and methods of their use.
• the amorphous form of a drug may exhibit different dissolution characteristics and different bioavaila bility patterns than its crystalline form(s), properties which can affect how the drug must be administered to achieve optimal effect.
• Amorphous and crystalline forms of a drug may also have different handling properties (e.g., flowa bility, compressibility), dissolution rates, solu bilities and sta bilities, all of which can affect the manufacture of dosage forms.
• Compounds may exist in one or more crystalline forms, but the existence and characteristics of those forms cannot be predicted with any certainty. And even after one polymorph has been identified, the existence and characteristics of other forms can only be determined by additional experimentation. Id.
• This invention is d irected, in part, to solid forms of the LI M kinase 2 inhibitor 3-(4-
• One em bodiment of the invention encompasses pharmaceutical compositions comprising the solid forms described herein. Another encompasses methods of treating,
• LEX-1312 managing, and/or preventing d iseases or d isorders affecting vision in a patient (e.g., glaucoma), which comprises administering to a patient a solid form of the invention.
• Figure 1 is an X-ray diffraction (X PD) pattern of crystalline l-(5-methyl-7H-pyrrolo [2,3- d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate benzoate.
• X PD X-ray diffraction
• the spectrum was obtained using a Rigaku M iniFlex instrument: Cu radiation (1.054056A ) with ⁇ ⁇ filter: 3 degree start angle; 45 degree stop angle, 0.02 degree sampling; 2 degree/minute scan speed.
• the sample material was dispersed on a zero-background sample holder.
• Figure 2 is an X-ray diffraction (XRPD) pattern of crystalline l-(5-methyl-7H-pyrrolo [2,3- d]pyrimidin-4-yl)piperid ine-4-carboxamido)phenyl dimethylcarbamate hydrochloride.
• XRPD X-ray diffraction
• Figure 3 is an X-ray diffraction (XRPD) pattern of crystalline l-(5-methyl-7H-pyrrolo [2,3- d]pyrimidin-4-yl)piperid ine-4-carboxamido)phenyl dimethylcarbamate phosphate.
• XRPD X-ray diffraction
• This invention is d irected, in part, to solid (e.g., crystalline) forms of 3-(4-(aminomethyl)- l-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl
• the compound which is an inhibitor of LI M kinase 2, and has been shown to decrease intraocular pressure in models of ophthalmic disease, and may be useful in the treatment, management, or prevention of glaucoma. See U.S. patent application pu blication US-2009-0264450-A1.
• This invention is also d irected to pharmaceutical compositions comprising solid forms of 3-(4-(aminomethyl)-l-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4- carboxamido)phenyl dimethylcarbamate, and to methods of their use.
• the terms “manage,” “managing” and “management” encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission.
• the terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.
• the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder. In other words, the terms encompass prophylaxis.
• a prophylactically effective amount of a compound is an amount sufficient to prevent a disease or condition, or one or more symptoms associated with the disease or condition, or to prevent its recurrence.
• a prophylactically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease or condition.
• the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
• a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition.
• a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or condition.
• the term "therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
• treat contemplate an action that occurs while a patient is suffering from the specified disease or disorder, which reduces the severity of the disease or disorder or one or more of its symptoms, or retards or slows the progression of the disease or disorder.
• This invention is directed to solid forms of 3-(4-(aminomethyl)-l-(5-methyl-7H- pyrrolo[2,3-d]pyrimidin-4-yl)pi ethylcarbamate:
• salts thereof Particular solid forms are crystalline.
• Specific salts include acetate, adipate, benzoate, besylate, fumarate, hydrochloride, maleate, nicotinate, and phosphate.
• One embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate.
• a particular form of this crystalline freebase has a differential scanning calorimeter (DSC) peak at about 177.9°C.
• DSC differential scanning calorimeter
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate acetate.
• a particular form provides an X-ray diffraction (XRPD) pattern containing peaks at one or more of about 5.9, 9.1, 12.0, 16.1, 17.2, 18.4, and/or 20.2 degrees 2 ⁇ .
• embodiment of the invention encompasses a crystalline acetate salt with an XRPD pattern having peaks at 5.9, 9.1, and 12.0 degrees 2 ⁇ . Another encompasses a crystalline acetate salt with an XRPD pattern having peaks at 12.0, 16.1, and 17.2 degrees 2 ⁇ . Another encompasses a crystalline acetate salt with an XRPD pattern having peaks at 12.0, 16.1, and 17.2degrees 2 ⁇ . 17.2, 18.4, and 20.2 degrees 2 ⁇ .
• the term "about” as used herein means ⁇ 0.3 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate adipate.
• a particular form provides an XRPD pattern containing peaks at one or more of about 5.6, 21.5, and/or 22.5 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
• LEX-1312 benzoate A particular form has a melting point of about 192.3°C as determined by DSC (onset temperature). A particular form has a DSC peak at about 194.5°C. A particular form provides an XRPD pattern containing peaks at one or more of about 6.5, 15.6, 16.5, 18.4, 19.2, 21.3, and/or 24.2 degrees 2 ⁇ . Thus, one embodiment of the invention encompasses a crystalline benzoate salt with an XRPD pattern having peaks at 6.5, 15.6, and 16.5 degrees 2 ⁇ . Another encompasses a crystalline benzoate salt with an XRPD pattern having peaks at 16.5, 18.4, and 19.2 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate besylate.
• a particular form provides an XRPD pattern containing peaks at one or more of about 5.6, 9.8, 15.0, 17.0, 19.6, 20.4, 22.7, and/or 24.8 degrees 2 ⁇ .
• one embodiment of the invention encompasses a crystalline besylate salt with an XRPD pattern having peaks at 5.6, 9.8, and 15.0 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate fumarate.
• a particular form provides an XRPD pattern containing peaks at one or more of about 6.4, 10.5, 15.6, 20.5, and/or 25.4 degrees 2 ⁇ .
• one embodiment of the invention encompasses a crystalline fumarate salt with an XRPD pattern having peaks at 6.4, 10.5, and 15.6 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate hydrochloride.
• a particular form is anhydrous.
• a particular form has a melting point of about 245.8°C as determined by DSC (onset temperature).
• a particular form has a DSC peak at about 248.9°C.
• a particular form provides an XRPD pattern containing peaks at one or more of a bout 6.4, 11.7, 17.0, 19.2, 23.0, and/or 25.7 degrees 2 ⁇ .
• one embodiment of the invention encompasses a crystalline hydrochloride salt with an XRPD pattern having peaks at 6.4, 11.7, and 17.0 degrees 2 ⁇ .
• hydrochloride salt with an XRPD pattern having peaks at 23.0 and 25.7 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate maleate.
• a particular form provides an XRPD pattern containing peaks at one or more of about 7.9, 15.9, 20.2, 24.0, 26.1, and/or 32.2 degrees 2 ⁇ .
• one embodiment of the invention encompasses a crystalline maleate salt with an XRPD pattern having peaks at 7.9, 15.9, and 20.2 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate nicotinate.
• a particular form provides an XRPD pattern containing peaks at one or more of about 8.3, 18.4, 25.1, 26.4, and/or 29.6 degrees 2 ⁇ .
• one embodiment of the invention encompasses a crystalline nicotinate salt with an XRPD pattern having peaks at 8.3, 18.4, and 25.1 degrees 2 ⁇ .
• Another embodiment of the invention encompasses crystalline 3-(4-(aminomethyl)-l-(5- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate phosphate.
• a particular form is a monohydrate.
• a particular form has a melting point of a bout 164.6°C as determined by DSC (onset temperature).
• a particular form has a DSC peak at about 170.9°C.
• a particular form provides an XRPD pattern containing peaks at one or more of a bout 4.5, 12.9, 16.0, 18.5, 20.3, 21.4, and/or 23.0 degrees 2 ⁇ .
• An example of a XRPD pattern of this crystalline form is provided in Figure 3.
• one embodiment of the invention encompasses a crystalline phosphate salt with an XRPD pattern having peaks at 4.5, 12.9, and 16.0 degrees 2 ⁇ .
• This invention encompasses solids that are mixtures of both amorphous and crystalline forms. Certain such solids comprise crystalline 3-(4-(aminomethyl)-l-(5-methyl-7H-pyrrolo[2,3- d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate or a pharmaceutically salt thereof in an amount of at least about 50, 75, 80, 85, 90, 95 or 99 weight percent.
• Crystalline forms of 3-(4-(aminomethyl)-l-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidine-4-carboxamido)phenyl dimethylcarbamate can be prepared from the amorphous freebase, the synthesis of which is described in U.S. patent application publication no. US-2009- 0264450-A1.
• crystalline salts can be obtained by selecting a solvent in which the
• LEX-1312 freebase is solu ble, adding to it the appropriate acid of the desired salt, and stirring and heating the mixture. Evaporation, cooling, and/or the addition of an antisolvent to the mixture can afford the desired salt, which can be collected by filtration.
• This invention encompasses a method of lowering intraocular pressure in a patient, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of the invention.
• Another embodiment encompasses a method of treating, managing or preventing a disease or disorder affecting vision in a patient, which comprises contacting the eye of the patient with a compound of the invention.
• Diseases and disorders affecting vision include glaucoma, neurodegenerative diseases, and infectious diseases.
• Compounds of the invention can be delivered to the eye (e.g., topically) using aqueous solutions, aqueous suspensions, and ointments.
• the ophthalmic product must be sterile in its final container to prevent microbial contamination of the eye.
• Preservatives may be used to maintain sterility once the container has been opened.
• Ophthalmic formulations also require that the pH, buffer capacity, viscosity, and tonicity of the formulation be controlled.
• Preferred formulations have a pH of from a bout 6.5 to 8.5, and a buffer capacity of from a bout 0.01 to 0.1.
• Particular formations are isotonic.
• Particular formations have a viscosity of from a bout 25 to 50 cps.
• API active pharmaceutical ingredient
• Appropriately buffered aqueous solutions may be used for the delivery of water solu ble compounds.
• polymeric ingredients are typically used to increase the composition's viscosity.
• suita ble polymers include cellulosic polymers (e.g., hydroxypropyl methylcellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose), synthetic polymers (e.g., carboxyvinyl polymers, polyvinyl alcohol), polysaccharides (e.g., xanthan gum, guar gum, and dextran), and mixtures thereof. See, e.g., U.S. patent nos. 4, 136,173 and
• Suspensions may also be used to deliver compounds.
• Polymeric ingredients are typically used in suspension compositions as physical sta bility aids, helping to keep the insolu ble ingredients suspended or easily redispersible. Id.
• Preservatives may be used to ensure the sterility of formations. Suitable preservatives include benzalkonium chloride, benzethonium chloride, chlorobutanol, phenylmercuric acetate, phenylmercuric nitrate, thimerosal, methylparaben, and propyl-parabens. And antioxidants may be used to ensure the stability of formations susceptible to oxidation. Suitable antioxidants include ethylenediaminetetraacetic acid, sodium bisulfite, sodium metabisulfite, and thiourea.
• compositions of the invention comprise a solid form of 3-(4- (aminomethyl)-l-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate, and are suitable for combining with one or more liquid vehicles to afford a final composition that is suitable for topical administration to the eye.
• Procedure B A reactor was charged with 3-(4-(aminomethyl)-l-(5-methyl-7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate freebase (101.1 mg, 0.224 mmol, 1 eq) and MeOH (1 mL). To the clear solution was added benzoic acid (33.9 mg, 0.278 mmol, 1.24 eq) and the resulting mixture was stirred at room temperature for 5 min to give a slurry. Acetonitrile (2 mL) was added and the slurry was heated to 70-73°C and stirred for 5 minutes to give a solution.
• the mixture was stirred for 10-30 minutes at 13°C, then added 12.0 kg of LP-911510 (24.4mol, 1.0 eq.), stirred for another 10-30 minutes at 13°C and then added 9.6 kg of N,N-diisopropylethylamine (74.3 mol, 3.0 eq.).
• the reaction mixture was then heated to 80-90°C for 20-22 hours. After cooled to 30-35°C, the mixture was transferred to a 500-L glass lined reactor, followed by an isopropanol (40 kg) rinse.
• This isopropanol addition/concentration process was repeated one more time with 39 kg isopropanol.
• the temperature of the mixture was lowered to 15-20°C and stirred at this temperature for about 12 hours.
• Isopropanol 11 kg was then added and the mixture was stirred at 15-20°C for about 3 hours.
• the slurry was filtered through a centrifuge. The reactor and the wet cake in the centrifuge was washed with 28 kg of isopropanol.
• the product was dried at 45-50°C under vacuum for 24 hours.
• the residual of ⁇ , ⁇ -diisopropylethylamine was mostly removed by stirring the product in 76 kg of water for 10-30 minutes.
• the mixture was stirred at 25-30°C for 15 hours while the pressure was maintained at 0.5-0.6MPa by regulating the hydrogen valve and pressure release valve. The hydrogen was released and purged with nitrogen.
• the mixture was passed through a kieselgur pad followed by an inline polish filter and the filtrate was collected in a drum.
• the reactor and the filters were washed 24 kg of methanol twice.
• the filtrate was combined and IPC analysis showed the residual palladium was 10 ppm vs. specification of NMT 15 ppm.
• the filtered solution was transferred into a 500 L glass lined reactor through an inline filter. The drum and the inline filter were rinsed with 18 kg of methanol and the wash was combined with the solution.
• the mixture was heated 50-60°C and stirred for 1-2 hours, then cooled to 0-5°C and stirred 2-3 hours.
• the slurry was filtered with a centrifuge and washed with 24 kg of filtered cold (-5-0°C) anhydrous ethanol. The wet cake was charged into a
• the prod uct was dried in oven at 45-50°C for a bout 20 hours and de-lumped with a sieve to afford 9.01 kg (91 % yield) crystalline anhydrous 3-(4-(a minomethyl)-l-(5-methyl-7H- pyrrolo [2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate hyd rochloride with a purity of 99.8%.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Ophthalmology & Optometry (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=45002136

Family Applications (1)

Country Status (16)

Cited By (1)

Citations (1)

Family Cites Families (1)

• 2011
  • 2011-11-01 TW TW100139812A patent/TW201302754A/zh unknown
  • 2011-11-03 US US13/288,321 patent/US8735408B2/en active Active
  • 2011-11-03 RU RU2013125755/04A patent/RU2013125755A/ru not_active Application Discontinuation
  • 2011-11-03 JP JP2013537811A patent/JP2013541588A/ja active Pending
  • 2011-11-03 KR KR1020137014386A patent/KR20140003433A/ko not_active Withdrawn
  • 2011-11-03 MX MX2013004923A patent/MX2013004923A/es not_active Application Discontinuation
  • 2011-11-03 WO PCT/US2011/059086 patent/WO2012061565A1/en not_active Ceased
  • 2011-11-03 SG SG2013033618A patent/SG190098A1/en unknown
  • 2011-11-03 AU AU2011323371A patent/AU2011323371A1/en not_active Abandoned
  • 2011-11-03 CN CN2011800533551A patent/CN103298815A/zh active Pending
  • 2011-11-03 CA CA2817112A patent/CA2817112A1/en not_active Abandoned
  • 2011-11-03 EP EP11785536.1A patent/EP2635584A1/en not_active Withdrawn
  • 2011-11-03 BR BR112013011094A patent/BR112013011094A2/pt not_active IP Right Cessation
  • 2011-11-04 AR ARP110104111A patent/AR083756A1/es unknown
• 2013
  • 2013-04-22 IL IL225884A patent/IL225884A0/en unknown
  • 2013-04-24 ZA ZA2013/02996A patent/ZA201302996B/en unknown

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events